REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

This early-stage trial tests a drug called palbociclib, alone or with other medicines, in people with leukemia that has returned or not responded to prior therapy. The main goal is to find the safest dose and understand side effects. About 32 adults aged 15 and older with acute m…

This study tests a new oral drug (revumenib) combined with chemotherapy for infants and young children with a hard-to-treat leukemia that has returned or not responded to treatment. The drug targets a specific genetic change (KMT2A rearrangement) that drives the cancer. The goal …

This study tests a new way to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a fast-growing blood cancer. It combines low-intensity chemotherapy with targeted drugs (ponatinib and blinatumomab) to kill cancer cells and help the immune system fight …

This study tested a treatment plan for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). The approach combined an immunotherapy drug (blinatumomab) with standard chemotherapy or another targeted drug (dasatinib). The goal was to see i…

This study tests a combination of two drugs, venetoclax and navitoclax, in children whose acute lymphoblastic leukemia has come back or not responded to treatment. The goal is to see if this combination can clear the leukemia from the bone marrow better than standard treatments. …

This early-phase study tests a new treatment for adults with acute lymphoblastic leukemia (ALL) that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to …

This early-stage study tests a new immune cell therapy for adults with a high-risk form of acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. Doctors take a patient's own white blood cells, add a special gene to help them recognize and attack can…